Andy Lin
Founding Partner @ Loyal Valley Capital
Shanghai, China
Andy Lin is a Series B investor at Loyal Valley Capital in Shanghai focused on Biotechnology and Health Care. Andy Lin is based out of Shanghai, Shanghai and is the Founding Partner of Loyal Valley Capital. Andy Lin previously worked at China Universal Asset Management as a CEO/Founder. Andy Lin attended the Harvard Business School.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Andy Lin invests in
Stages Andy Lin invests in
Countries Andy Lin invests in
Investment Focus
Industry
- Biotechnology 3 (100%)
- Health Care 2 (67%)
- Medical 1 (33%)
- Genetics 1 (33%)
- Biopharma 1 (33%)
Stage
- Series B 2 (67%)
- Series D 1 (33%)
Country
- China 2 (67%)
- United States 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
EdiGene
|
EdiGene is dedicated to the development of genome editing technology for human health. Genome editing technology enables the targeted modification of genetic information in human cells, including gene knockout, knock-in and targeted mutations. They aim at providing the high quality products and services for the patients, the pharmaceuticalindustry, and the scientific research community with the most advanced genome editing technology.EdiGene innovates and applies genome editing technology to developing human therapeutic products. Their therapeutic approach is to treat diseases at the molecular level, making gene therapy safer and more effective. | $61.6M / Series B / Apr 21, 2021 | |
Regor Therapeutics
|
Regor Therapeutics is a clinical-stage company dedicated to the discovery and development of innovative and clinically differentiated medicines by leveraging the proprietary CARD (Computer Accelerated Rational Discovery) Platform, seamlessly integrating structural biology, computational chemistry, therapeutic biology, medicinal chemistry, andclinical development. Regor has assembled a world-class scientific team and demonstrated high efficiency in producing best- and first-in-class molecules. | $90M / Series B / Feb 18, 2021 | |
Akeso Biopharma
|
The company has built a global level of bio-pharmaceutical research and development and industrialization platform; established for cancer, autoimmune diseases, inflammation and cardiovascular disease of the rich product line. The scale of the company's platform, hardware and software facilities, the number of new drug product lines, R &D team in the country are the same industry-leading level. Kang Fang biological has been with the international and domestic listed pharmaceutical companies to establish a cooperative relationship, the joint development of innovative antibodies to new drugs, is a strategic cooperation in the form of development of new drugs in the forerunner. | $150M / Series D / Nov 04, 2019 |
Co-Investors
About Loyal Valley Capital
Loyal Valley Capital is a thematic, research-driven private equity firm.
Loyal Valley Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jay Gu
Managing Director
|
|||
Roy Xie
Managing Director and Head of Healthcare Investments
|
|||
|
Andy Lin
Founding Partner
|
|||
Chengbin Li
Partner
|
|||
Jason Zhao
Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Andy Lin invest in?
Andy Lin invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series D stage. Most of the 3 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Andy Lin last invest?
The most recent investment recorded for Andy Lin closed in Apr 2021. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
